| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | MCART1 |
| Uniprot No | Q9H1U9 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 1-297aa |
| 活性数据 | MMDSEAHEKRPPILTSSKQDISPHITNVGEMKHYLCGCCAAFNNVAITFPIQKVLFRQQLYGIKTRDAILQLRRDGFRNLYRGILPPLMQKTTTLALMFGLYEDLSCLLHKHVSAPEFATSGVAAVLAGTTEAIFTPLERVQTLLQDHKHHDKFTNTYQAFKALKCHGIGEYYRGLVPILFRNGLSNVLFFGLRGPIKEHLPTATTHSAHLVNDFICGGLLGAMLGFLFFPINVVKTRIQSQIGGEFQSFPKVFQKIWLERDRKLINLFRGAHLNYHRSLISWGIINATYEFLLKVI |
| 分子量 | 60.1 kDa |
| 蛋白标签 | GST-tag at N-terminal |
| 缓冲液 | 0 |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于重组人MCART1蛋白的示例参考文献，内容为虚构的典型研究方向，供参考：
---
1. **文献名称**：Recombinant Expression and Functional Characterization of Human MCART1 in Mitochondrial NAD+ Transport
**作者**：Smith, J. et al.
**摘要**：本研究成功在大肠杆菌中表达并纯化重组人MCART1蛋白，通过体外实验证实其介导线粒体膜对NAD+的转运活性，揭示了MCART1在细胞能量代谢中的关键作用。
2. **文献名称**：MCART1 Overexpression Alters Glycolytic Flux in Colorectal Cancer Cells
**作者**：Zhang, L. et al.
**摘要**：文章探讨了重组MCART1蛋白在结肠癌细胞中的功能，发现其过表达通过增强线粒体氧化磷酸化抑制糖酵解，提示MCART1可能成为癌症代谢疗法的潜在靶点。
3. **文献名称**：Structural Insights into MCART1 as a Mitochondrial Solute Carrier
**作者**：Johnson, R.B. & Lee, S.
**摘要**：通过X射线晶体学解析重组MCART1的三维结构，阐明其底物结合域及转运机制，为设计靶向MCART1的小分子药物提供结构基础。
4. **文献名称**：MCART1 Mutations Linked to Familial Mitochondrial Encephalopathy: Functional Rescue by Recombinant Protein Therapy
**作者**：Garcia, M. et al.
**摘要**：研究发现MCART1基因突变导致线粒体脑病，利用重组MCART1蛋白在患者细胞模型中部分恢复线粒体功能，证实其治疗潜力。
---
**备注**：以上文献为示例，实际研究中请结合具体数据库(如PubMed、Web of Science)检索真实文献。MCART1(又称SLC25A51)的研究多聚焦于线粒体NAD+转运及代谢疾病关联。
MCART1 (Mitochondrial Carrier Triple Repeat Protein 1), also known as SLC25A51. is a member of the solute carrier 25 (SLC25) family, which primarily facilitates the transport of metabolites across mitochondrial membranes. This protein plays a critical role in regulating cellular energy metabolism by functioning as a NAD\(^+\) transporter, essential for maintaining mitochondrial NAD\(^+\) levels and supporting oxidative phosphorylation. Dysregulation of MCART1 has been implicated in metabolic disorders, neurodegenerative diseases, and cancer due to its influence on mitochondrial function and redox balance.
Recombinant human MCART1 protein is produced using heterologous expression systems (e.g., E. coli or mammalian cells) to enable functional and structural studies. Its recombinant form retains the ability to integrate into lipid membranes and mediate substrate transport. Researchers utilize this protein to investigate its role in cellular energetics, aging-related pathways, and disease mechanisms. Additionally, it serves as a tool for screening potential therapeutics targeting mitochondrial dysfunction. As a relatively newly characterized transporter, MCART1 continues to be a focus of studies aiming to clarify its regulatory mechanisms and therapeutic potential in pathologies linked to mitochondrial insufficiency.
×
